---
title: "Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285145408.md"
description: "Chardan Capital has reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $76.00. Analyst Geulah Livshits, a 5-star analyst with a 12.7% average return, highlights a Moderate Buy consensus rating for the stock, with an average price target of $72.33. Livshits also covers other healthcare stocks like Palvella Therapeutics and Iovance Biotherapeutics."
datetime: "2026-05-05T02:35:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285145408.md)
  - [en](https://longbridge.com/en/news/285145408.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285145408.md)
---

# Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)

In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Crispr Therapeutics AG, with a price target of $76.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Livshits is a 5-star analyst with an average return of 12.7% and a 37.88% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Iovance Biotherapeutics, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $72.33 average price target.

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)
- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)
- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)
- [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)